Welcome to our dedicated page for INTEGRA LIFESCIENCES HOLDINGS SEC filings (Ticker: IART), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on INTEGRA LIFESCIENCES HOLDINGS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into INTEGRA LIFESCIENCES HOLDINGS's regulatory disclosures and financial reporting.
Integra LifeSciences Holdings Corp’s common stock has a reported significant shareholder, Paradigm Capital Management, Inc., as updated in an amended ownership report. Paradigm Capital Management, a New York S corporation based in Albany, reports beneficial ownership of 3,439,098 shares of Integra LifeSciences common stock.
This position represents 4.42% of the outstanding common stock of Integra LifeSciences. Paradigm Capital Management reports sole power to vote and dispose of all 3,439,098 shares, with no shared voting or dispositive power. The filing characterizes the holding as ownership of 5 percent or less of the class, reflecting its current status relative to regulatory reporting thresholds.
Vanguard Portfolio Management reports beneficial ownership of common stock of Integra LifeSciences Holdings Corp. The filing states beneficial ownership of 3,912,816 shares, representing 5.02% of the class as of June 30, 2026.
Vanguard Portfolio Management has sole voting power over 169,723 shares and sole dispositive power over all 3,912,816 shares, with no shared voting or dispositive power. The position reflects securities held by Vanguard Portfolio Management LLC and specified Vanguard affiliates and funds for which they exercise dispositive and/or voting power. No other single person has an interest in more than 5% of these securities.
Integra LifeSciences Holdings Corporation reported modestly higher revenue and a return to profitability in Q2 2026. Total revenue was $418,761 thousand for the quarter and $810,679 thousand for the first half of 2026, slightly above the prior-year periods.
Q2 2026 net income was $4,482 thousand, compared with a net loss of $484,073 thousand in Q2 2025, when results included a $511,365 thousand goodwill impairment charge. Operating income for the first half improved to $30,755 thousand from a loss of $528,171 thousand a year earlier.
Cash and cash equivalents were $214,415 thousand and short-term investments $59,669 thousand at June 30, 2026. Total debt had a carrying value of $1,872,299 thousand. Net cash provided by operating activities for the first six months was $32,605 thousand, versus $(2,338) thousand in 2025.
Integra LifeSciences reported second-quarter 2026 net revenue of $418.8 million, up 0.8% reported and 0.7% organic year over year. GAAP gross margin improved to 52.5% from 50.4%, while adjusted gross margin rose to 61.3% from 60.7%.
GAAP net income was $4.5 million, or $0.06 per diluted share, compared with a GAAP net loss of $484.1 million, or $(6.31) per share, a year ago, which included a large goodwill impairment. Adjusted net income increased to $43.7 million, or $0.56 per diluted share, from $34.4 million, or $0.45 per share. Adjusted EBITDA was $78.4 million, or 18.7% of revenue.
Specialty Surgery revenue grew 1.7% to $309.3 million, while Tissue Reconstruction declined 1.9% to $109.5 million. The company generated $22.8 million of operating cash flow, with net debt of $1.6 billion and a 4.1x leverage ratio. For Q3 2026, Integra guides to revenue of $410–$425 million and adjusted EPS of $0.53–$0.61. Full-year 2026 reported revenue guidance is now $1.654–$1.695 billion, with organic revenue growth of 0.8%–3.3% and adjusted EPS of $2.40–$2.50. The Braintree facility has begun production, supporting a planned fourth-quarter 2026 relaunch of SurgiMend.
INTEGRA LIFESCIENCES HOLDINGS CORP senior vice president and principal accounting officer Jeffrey Mosebrook reported a tax-related share disposition. On this Form 4, 937 shares of common stock were delivered at $17.89 per share to satisfy tax obligations, leaving him with 34,516 directly held shares.
Singh Harvinder reported acquisition or exercise transactions in this Form 4 filing.
Integra LifeSciences EVP & President, SS Harvinder Singh received a grant of 5,590 restricted stock units (RSUs). The award was made under the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan.
Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in three equal annual installments on the first, second, and third anniversaries of the grant date, subject to his continued service. Following this grant, Singh holds 68,883 RSUs directly.
DAVIS ROBERT T. JR. reported acquisition or exercise transactions in this Form 4 filing.
Integra LifeSciences Holdings Corp executive Robert T. Davis Jr., EVP & President, TR&DT, received a grant of 11,180 restricted stock units (RSUs) tied to the company’s common stock. These RSUs were awarded under the company’s Fifth Amended and Restated 2003 Equity Incentive Plan as part of equity compensation.
Each RSU represents a contingent right to receive one share of common stock and will vest in full on the second anniversary of the grant date, assuming he continues in service through that date. Following this award, Davis directly holds 54,530 RSUs in total.
INTEGRA LIFESCIENCES HOLDINGS CORP Executive Vice President and Chief Financial Officer Lea Daniels Knight reported a routine tax-related share disposition. On this Form 4, 5,226 shares of common stock were withheld at $18.05 per share to satisfy tax obligations, leaving her with 45,263 directly held shares.
INTEGRA LIFESCIENCES HOLDINGS CORP executive Michael J. McBreen, EVP & Chief Commercial Officer, received equity awards as part of his compensation. He was granted 31,909 restricted stock units and a non-qualified stock option for 60,372 shares at an exercise price of $15.67 per share. Both awards vest in three equal annual installments starting on the first anniversary of the grant date, contingent on his continued service. Following the RSU grant, he holds 124,017 shares of common stock directly.
Integra LifeSciences Holdings Corp President and CEO Stuart Essig received significant equity awards as compensation. On 6/1/2026, he was granted 365,297 restricted stock units, each representing one share of common stock, and 705,468 non-qualified stock options with a conversion price of $15.6700 per share.
The option award consists of 482,976 options granted under his employment agreement and 222,492 options granted at the Compensation Committee’s discretion. The RSU award consists of 255,265 RSUs under the employment agreement and 110,032 RSUs granted by the Compensation Committee.
All awards were granted under the company’s equity incentive plan and will vest one-third on the first anniversary of 5/1/2026, then in monthly installments over the following twenty-four months, subject to his continued service. These are grants/awards, not open-market purchases or sales.